{"preliminary_commentary":{"by_channel":{"x_thread":10},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05642780\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"SKB264-II-06","nct_id":"NCT05642780","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skb264-ii-06-nct05642780. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"subjects will receive SKB264 in combination with pembrolizumab by intravenous administration","label":"cohort A","type":"EXPERIMENTAL"},{"description":"subjects will receive SKB264 in combination with pembrolizumab by intravenous administration","label":"cohort B","type":"EXPERIMENTAL"},{"description":"subjects will receive SKB264 in combination with pembrolizumab by intravenous administration","label":"cohort C","type":"EXPERIMENTAL"},{"description":"subjects will receive SKB264 in combination with pembrolizumab by intravenous administration","label":"cohort D","type":"EXPERIMENTAL"},{"description":"subjects will receive SKB264 in combination with pembrolizumab by intravenous administration","label":"Cohort E","type":"EXPERIMENTAL"}],"collaborators":["Myriad Genetics, Inc.","Discovery Life Sciences, LLC","Ventana Medical Systems, Inc","Frontage Laboratories, Inc.","Clario"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Solid Tumor"],"enrollment":{"count":240,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SKB264","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2025-10-14","lead_sponsor":"Klus Pharma Inc.","official_title":"A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose limiting toxicity (DLT) and adverse events (AEs)","timeFrame":"From subject sign the ICF to 30 days after the last dose of study treatment"},{"measure":"Objective Response Rate (ORR)","timeFrame":"From baseline until disease progression, death or other protocol defined reason up to approximately 21 months"},{"measure":"Prostate-specific antigen (PSA) response rate (Cohort D)","timeFrame":"From baseline until disease progression, death or other protocol defined reason up to approximately 21 months"}],"references":[],"start_date":{"date":"2023-01-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05642780"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skb264-ii-06-nct05642780"}